Circulating Tumor DNA Using Tagged Targeted Deep Sequencing to Assess Minimal Residual Disease in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Table 1

Demographics and pathological data of the studied cohort.

UPN	Age at diagnosis (years)	Baseline	ER	HER2	Ki-67 (%)	Pre surg stg	Surg stg	pCR
1	37	cT2(40)N1	+	−	40	cT2(35)N0	pT3N2a	No
2	63	cT2(40)N0	+	+	10	cT1(1)cN0	ympT1cN1a	No
3	39	cT2(24)N0	+	−	70	cT0N0	ypTisN0	Yes
4	73	cT2(30)N1	+	−	16	cmT1(8)bN0	ypT1bN1a	No
5	44	cmT2(24)N0	+	+	60	cT0N0	ypCR	Yes
6	55	cT2(43)N1	+	−	10	cT1(12)cN0	ypT1aN0	No
7	61	cT2(22)N0	+	−	90	cT0N0	ypCR	Yes
8	54	cT3(60)N0	+	−	10	cT0N0	ypT1cN0	No
9	44	cT3(72)N1	+	−	45	cT1(10)N0	ypT1cN1a	No
10	32	cT3(90)N1	+	−	70	cT1(12)cN0	ypT3N2a	No

UPN = unique patient number. Baseline = clinical stage at diagnosis, before NACT. Pre surg stg = clinical staging before surgery and after NACT. Surg stg = pathological staging at surgery. pCR = pathological complete response.